Drospirenone‐containing oral contraceptive pills and the risk of venous and arterial thrombosis: a systematic review

@article{Wu2013DrospirenonecontainingOC,
  title={Drospirenone‐containing oral contraceptive pills and the risk of venous and arterial thrombosis: a systematic review},
  author={CQ Wu and SM Grandi and KB Filion and Haim Arie Abenhaim and L. Joseph and MJ Eisenberg},
  journal={BJOG: An International Journal of Obstetrics \& Gynaecology},
  year={2013},
  volume={120},
  pages={801 - 811}
}
Previous studies have provided conflicting results regarding the effect of drospirenone‐containing oral contraceptive pills (OCPs) on the risk of venous and arterial thrombosis. 

Drospirenone‐containing oral contraceptive pills and the risk of venous thromboembolism: a systematic review of observational studies

The effects of fourth‐generation drospirenone‐containing combined oral contraceptives (COCs) on the risk of venous thromboembolism (VTE) are controversial.

Drospirenone-containing oral contraceptives and venous thromboembolism: an analysis of the FAERS database

An analysis using the US Food and Drug Administration’s Adverse Event Reporting System shows that venous thrombotic events continue to be reported at a much higher rate with drospirenone-containing oral contraceptives than the general background.

Drospirenone enhances GPIb‐IX‐V‐mediated platelet activation

This data indicates that using drospirenone‐containing contraceptives is associated with an increased risk of thrombosis in women, but the underlying causality is unclear.

Epidemiology of hormonal contraceptives-related venous thromboembolism.

Current data support that newer generation formulations of hormonal contraceptives as well as non-oral hormonal contraceptives seem to be more thrombogenic than second-generation hormonal contraceptives.

MECHANISMS IN ENDOCRINOLOGY Epidemiology of hormonal contraceptives-related venous thromboembolism

Current data support that newer generation formulations of hormonal contraceptives as well as non-oral hormonal contraceptives seem to be more thrombogenic than second-generation hormonal contraceptives.

Drospirenone-containing oral contraceptives may increase the risk of venous thromboembolism

  • S. Jick
  • Medicine
    Evidence-Based Nursing
  • 2013
Commentary on: Wu CQ, Grandi SM, Filion KB, et al. Drospirenone-containing oral contraceptive pills and the risk of venous and arterial thrombosis: a systematic review. BJOG

Oral Contraceptives: Benefits and Risks

Oral contraceptives remain one of the most commonly used hormonal contraceptives worldwide and there are few medical conditions that would pose an unacceptable health risk to use of the progestogen-only pill.

The Risk of Venous Thromboembolism with Different Generation of Oral Contraceptives; a Systematic Review and Meta-Analysis

It seems that the risk of VTE is not same between different generations of OCs, so that third-generation has highest risk.

Oral Steroid Contraception

This review highlights the available formulations of oral contraceptives along with their evidence-based associated risks and benefits and highlights the future directions for development of novel oral contraceptives.
...

References

SHOWING 1-10 OF 44 REFERENCES

Deep vein thrombosis associated with the new oral contraceptive Yasmin.

  • T. H. Oo
  • Medicine
    Southern medical journal
  • 2009
It is stated that although Yasmin might be safer in terms of venous thromboembolism cases have been reported, a case of a healthy 28-year-old woman who developed deep vein thrombosis (DVT) while on Yasmin is summarized.

Combination Estrogen–Progestin Oral Contraceptives

A healthy, sexually active, 35-year-old woman presents for advice about the use of oral contraceptives. She does not smoke cigarettes and has no personal or family history of venous thromboembolism,

Difference between drospirenone-containing oral contraceptives and other oral contraceptives related to risk of venous thromboembolism

This short study was conducted during the 3-year period 2008–2010 using data on drug utilisation and data on side effects from the Agency for Medicinal Products and Medical Devices of Croatia (HALMED).

Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study

Use of drospirenone-containing oral contraceptives was associated with an increased risk of deep vein thrombosis and pulmonary embolism, but not transient ischemic attack or cerebrovascular attack, relative to second- and third-generation combined oral contraceptives.

Myocardial infarction and spontaneous dissection of coronary artery due to oral contraceptive.

This letter to the editor reports on a case of third-generation oral contraceptive pill use associated with spontaneous coronary dissection of the left coronary artery and proximal thrombotic

Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study

The study confirms that COC use is associated with an increased risk of VTE, and the VTE ORs (adjusted and crude) that compared DNG/EE and DRSP/EE with other low-dose COCs were close to unity and do not indicate a higher risk for users of D NG/EE or DR SP/EE.

Safety of a New Oral Contraceptive Containing Drospirenone

Overall, the safety data with EE/DRSP and other OCs indicate that these products have no negative impact on the risk of VTE (and other adverse events) in women who receive OCs for contraception.

The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study

A high risk of venous thrombosis during the first months of oral contraceptive use irrespective of the type of oral contraceptives is confirmed, and many women do not use the safest brands.

Update on combined oral contraceptives: risk of venous thromboembolism. Drospirenone versus other progestins

This case adds further information to the recently published epidemiological studies that suggest an increased risk of VTE associated with drospirenone (DRSP) and other progestins.

Acute Myocardial Infarction Associated With Yasmin Oral Contraceptive

  • G. OrtíY. MiraA. Vayá
  • Medicine
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • 2007
The new third-generation contraceptive Yasmin has certain characteristics that differentiate it from others because it has a lower estrogen component in its composition compared with previous oral contraceptives, but there is no difference at the chemical level in thrombosis risk.